In this segment, Barratt reflects on recent updates in the management of IgA nephropathy.
Back
Understanding Recent Updates in IgA Nephropathy Pipeline
Understanding Recent Updates in IgA Nephropathy Pipeline
Episodes
All
All
In this segment, Barratt reflects on recent updates from the SPARTAN trial examining use of sparsentan as a first-line therapy in IgAN.
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, particularly data on long-term use of Nefecon.
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on felzartamab.
In this segment, Barratt reflects on recent updates in the management of IgA nephropathy, with a focus on updates related to atrasentan.
Advertisement
Advertisement
Trending on HCPLive
1
VESALIUS-CV: Evolocumab Prevents Cardiovascular Disease in High-Risk Diabetes
2
Socrodeucitinib Meets Primary Endpoint in Phase 2 Psoriasis Study
3
After Sickle Cell Gene Therapy, What Comes Next?
4
New Liver Cancer BEACON-HCC Framework Shows 96.6% Concordance in Pilot
5